Truvada is the first antiretroviral drug to be licensed in all 28 countries of the European Union to reduce the risk for HIV infection, subject to national regulatory authority approval of required pharmacovigilance materials in each country.
Two major studies (iPrEx study and Partners PrEP trial) demonstrated substantial reductions in the risk for HIV-1 infection when Truvada was used as PrEP. Both studies linked better adherence to daily Truvada to better protection against HIV-1 infection.
Experts believe that it will be available on the pharmaceutical market in the next six months. Even now PrEP plays an important role, together with other measures, in HIV prevention.
PrEP is relatively costly (universally recognized is $1,539.90 for 30 tablets) if it is not reimbursed by health insurance and is affordable by very few people. Now many hope that alternative PrEP becomes available in the market and that this very effective method of prevention will be available to many more.
It is not yet clear when PrEP will be available in Sweden and at what cost.
In addition to the European Union, Truvada is also authorized for PrEP in the United States, Australia, Canada, Kenya, Peru, and South Africa.